A First-in-human Clinical Trial to Test if the Investigational Drug BNT3219 is Safe and Potentially Beneficial for People With Advanced Solid Tumors When Given Alone or Together With Other Investigational Drugs
brief summary
This study will test BNT3219 (also known as PM1092) in adults with advanced solid tumors whose cancer has progressed after available standard treatments. It is the first study of BNT3219 in people, and it will test different dose levels to identify safe and tolerable doses. The study will also examine how the treatment moves through the body, whether the immune system reacts to them, and whether it shows signs of shrinking or controlling tumors.
detailed description
This study will initiate with Part A which will consist of a dose escalation and dose expansion of BNT3219 monotherapy. The dose expansion will be conducted in some specific indications with the recommended phase II dose (RP2D) generated from the dose escalation.
The sponsor will analyze all available data from Part A and may decide to continue the study with Part B to investigate BNT3219 in combination with other investigational therapies.
There will be a Screening Period, a Treatment Period, and a Follow-up Period (including an end-of-treatment visit, two safety follow-up visits, and a survival follow-up period with regular visits).
Participants will remain in the survival follow-up period until death, lost to follow-up, withdrawal of consent, or until the sponsor terminates the study, whichever occurs first.
official title
A Phase I/Ib, First-in-human, Open-label, Multi-site, Multi-regional, Dose Escalation Trial With Expansion Cohorts to Evaluate Safety and Preliminary Efficacy of BNT3219 Monotherapy or BNT3219 in Combination With Other Investigational Therapies in Participants With Advanced Solid Tumors